

Edgar Filing: CBOT HOLDINGS INC - Form 425

CBOT HOLDINGS INC
Form 425
June 25, 2007

Filed by Chicago Mercantile Exchange Holdings Inc. pursuant
to Rule 425 under the Securities Act of 1933, as amended, and
deemed filed pursuant to Rule 14a-6 under the
Securities Exchange Act of 1934, as amended.

Subject Company: CBOT Holdings, Inc.

Subject Company's Commission File No.:001-32650

CME/CBOT MERGER:

THE RIGHT TRADE FOR CBOT

MEMBERS AND SHAREHOLDERS

	CME/CBOT MERGER	ICE PROPOSAL
LONG-TERM POTENTIAL	Creates world's largest and most valuable exchange, best positioned to compete and thrive in today's globally competitive environment	Combination with niche player does not materially enhance CBOT's position
GROWTH OPPORTUNITIES	Largest player in every major asset class with most liquid benchmark products and strongest distribution network, trading platforms and clearing capabilities; More OTC and spot market opportunities; More potential revenue synergies from complementary products; Stronger history of and potential for product innovation	More limited growth opportunities; Flattening volume; Limited track record; Speculative synergy projections
SHAREHOLDER VALUE	Combined market capitalization of roughly \$30 billion; Diversity of revenue and strong balance sheet positions shareholders to benefit from new organic growth opportunities, as well as mergers, acquisitions and partnerships	Value of ICE stock not trading on fundamentals; Undervalued ERP proposal; Uncertain synergies
MEMBER BENEFITS	Superior cash dividend, ERP solution and fixed price tender offer provides greater flexibility and upside potential; Protects core rights and tiered pricing for member liquidity providers; Preserves common clearing link and \$1 billion in margin efficiencies; Consolidation of floor and trading platforms creates \$70 million in member savings opportunities	History of less-favorable member pricing, declining seat values; Lack of consolidated trading floors and platforms
ABILITY TO INTEGRATE	Ready to start seamless integration on Day One, with minimal risk and no distraction from new growth opportunities	Catastrophic integration risk; Questionable clearing and technology; Independent experts predict at least two years to complete integration

▶ YES

The Choice Is Clear: Vote *For* the CME/CBOT merger by July 9th!

For additional information, contact

DF King & Co., Inc. at 1-800-769-7666

For additional information, contact

Georgeson, Inc. at 1-866-834-7793

Forward-Looking Statements This advertisement may contain forward-looking information regarding Chicago Mercantile Exchange Holdings Inc. and CBOT Holdings, Inc. and the combined company after the completion of the merger that is intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. The actual results or performance by CME or CBOT or the combined company, and issues relating to the transaction, could differ materially from those expressed in, or implied by, any forward-looking statements relating to those matters. Information regarding the risks that may affect the parties' performance and the performance of the combined company can be found in their filings with the Securities and Exchange Commission, including Item 1A of CME's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, their most recent quarterly reports on Form 10-Q and their definitive joint proxy statement/prospectus, as supplemented. Copies of said reports are available online at <http://www.sec.gov> or on request from the CME. You should not place undue reliance on forward-looking statements, which speak only as of the date of this advertisement. Except for any obligation to disclose material information under the Federal securities laws, CME undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this advertisement.

Edgar Filing: CBOT HOLDINGS INC - Form 425

Additional Information CME and CBOT have filed a definitive joint proxy statement/prospectus with the Securities and Exchange Commission (SEC) in connection with the proposed transaction. The parties intend to file a supplement to the joint proxy statement/prospectus and mail such supplement to CME and CBOT shareholders as of the record date for the special meetings. This advertisement is not a substitute for the definitive joint proxy statement/prospectus, as supplemented, or any other documents CME and CBOT have filed or will file with the SEC. Investors and security holders are urged to read the definitive joint proxy statement/prospectus, as supplemented, and any other relevant documents filed or to be filed by CME or CBOT because they contain or will contain important information about the proposed transaction. The definitive joint proxy statement/prospectus is, and the supplement thereto and other documents filed or to be filed by CME and CBOT with the SEC are or will be, available free of charge at the SEC's Web site (www.sec.gov) or from Chicago Mercantile Exchange Holdings Inc., Shareholder Relations and Membership Services, 20 South Wacker Drive, Chicago, Illinois 60606, Attention: Beth Hausoul.

CME and its directors, executive officers and other employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information regarding CME's directors and executive officers is available in CME's proxy statement for its 2007 annual meeting of shareholders, dated March 17, 2007. Additional information regarding the interests of such potential participants is available in the definitive joint proxy statement/prospectus, as supplemented, and the other relevant documents filed with the SEC. CBOT and its directors, executive officers and other employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information regarding CBOT directors and executive officers is available in CBOT's proxy statement for its 2007 annual meeting of stockholders, dated March 29, 2007. Additional information regarding the interests of such potential participants is included in the joint proxy statement/prospectus and the other relevant documents filed with the SEC.

June 25, 2007

SETTING THE RECORD STRAIGHT ON THE CME/CBOT MERGER:

KNOW THE RISKS OF DEALING WITH ICE

Dear CBOT Shareholders:

We are sending this letter to set the record straight and make sure that all CBOT members and shareholders have the facts they need to see through the ICE propaganda and understand the significant risks of their proposal.

ICE Offers a Riskier Currency

The current ICE stock price is clearly being driven by a takeover premium, not by fundamentals. But don't just take our word for it. The financial community has issued a number of clear warnings about the risk of ICE's stock:

Bank of Montreal: *If it became evident ICE would win [CBOT], ICE stock would fall substantially.* Mike Vinciguerra 6/14/07

Bank of America: *Takeout speculation has been fueling the stock of late, but we do not believe a takeout is likely near-term. And while fundamentals have been decent, we are not sure they are strong enough to support the stock at current levels.* Chris Allen 6/14/07

Goldman Sachs: *The biggest risk to our price target is ICE's potential acquisition of BOT. While the transaction would have attractive long term accretion, there are significant hurdles to completing the integration. Further, should NYMEX attract a larger share of commodity volumes or the global OTC market slow, earnings could underperform our expectations.* Daniel Harris 6/14/07

CIBC: *We believe that ICE's stock has traded higher since the CME revised offer in expectation that ICE would not succeed in its bid attempt and would itself become a takeover target.* Niamh Alexander 6/13/07

Deutsche Bank: *We believe ICE would have to raise its bid substantially to overcome CME's operational advantage, with DOJ approval, and that any new bid could pressure ICE shares to the downside.* Rob Rutschow 6/13/07

Credit Suisse: *We believe the greatest near-term risk to our ICE call relates to its bid to merge with CBOT. We believe a successful bid would likely lead to sizeable equity issuance/earnings dilution, higher investment spending and integration risk while dampening ICE's stand-alone high growth franchise.* Howard Chen 6/11/07

ICE Provides a High Risk Proposition

The facts are clear. ICE does not have the technology or clearing capabilities to manage CBOT business. To accommodate your trading activity, ICE Clear will have to increase its clearing capacity by thirteen times NYBOT's average daily transactions and nineteen times its peak transactions. To handle your electronic trading volume on its platform, ICE will have to increase its technology capacity by six times to handle an average CBOT day and ten times to handle your peak days. Again, you don't have to take our word for it.

Richard Dennis, Independent Trader: *When it comes to the reliability of trading platforms, the Merc is a nine, the Board of Trade is a six and ICE is a one, (Richard) Dennis told the Sun-Times. He said that of all the trading glitches he encounters, 80 percent of them are due to ICE and the rest equally to the Board of Trade and the Merc.* Chicago Sun-Times 6/21/07

Computer Sciences Corporation, an independent technology consulting firm: *transferring to the ICE platform would create substantial risk to CBOT and its pools of liquidity.* CSC Report May 2007

Keep in mind that ICE is still integrating NYBOT and NGX; it still needs to integrate ChemConnect; it still needs to build new data centers; it still needs to build out NYBOT's clearing; it still needs to build a London clearing operation; and it just announced another merger with the Winnipeg Commodity Exchange.

ICE Wants to Minimize the Value of Your CBOE Exercise Rights

Through its proposal with CBOE, ICE has undervalued your exercise rights. Why have CBOE and ICE drastically undervalued the ERP, offering to buy out your ERPs for a fraction of their value? Do you really trust that ICE and CBOE will protect that value? In contrast, CME and CBOT have now provided a minimum value of \$500,000 per ERP along with the upside to unlock the full value.

Jerry Zordani, CBOT member: *The Merc's latest offer is very compelling. It preserves the exercise rights.* Chicago Tribune 6/15/2007

CBOT/CME Merger is the Right Trade for CBOT Members and Shareholders

A CBOT/CME combination delivers real and immediate and long-term benefits for members, shareholders and customers. Together, we will be the industry's leading exchange with a powerful growth strategy. We will offer the most world's most diverse

derivatives product line available via state of the art trading platform or floor. We will have world-class clearing that will continue to provide over \$1 billion in margin efficiencies. We will continue our collective tradition of providing preferred pricing for high volume producers. We have regulatory clearance. And we are ready to integrate today and can begin delivering value immediately.

As members and shareholders of CBOT Holdings you are sophisticated market participants. You understand risk. On July 9, the choice is clear: vote **YES** on a CBOT/CME combination.

Sincerely,

Forward-Looking Statements

This press release may contain forward-looking information regarding Chicago Mercantile Exchange Holdings Inc. and CBOT Holdings, Inc. and the combined company after the completion of the merger that is intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the benefits of the business combination transaction involving CME and CBOT, including future financial and operating results, the new company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based on current beliefs, expectations, forecasts and assumptions of CME's and CBOT's management which are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Other risks and uncertainties relating to the proposed transaction include, but are not limited to, the satisfaction of conditions to closing, including receipt of shareholder, member, antitrust, regulatory and other approvals on the proposed terms; the proposed transaction may not be consummated on the proposed terms; uncertainty of the expected financial performance of the combined company following completion of the proposed transaction; the combined company may not be able to achieve the expected cost savings, synergies and other strategic benefits as a result of the proposed transaction; the integration of CBOT's operations with CME's may not be successful or may be materially delayed or may be more costly or difficult than expected; general industry and market conditions; general domestic and international economic conditions; and governmental laws and regulations affecting domestic and foreign operations.

More information regarding other risks that may affect the parties' performance can be found in their filings with the Securities and Exchange Commission, including Item 1A of CME's Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and their most recent quarterly reports on Form 10-Q. Copies of said reports are available online at <http://www.sec.gov> or on request from the CME. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Except for any obligation to disclose material information under the Federal securities laws, CME undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this press release.

Additional Information

CME and CBOT have filed a definitive joint proxy statement/prospectus with the Securities and Exchange Commission (SEC) in connection with the proposed transaction. The parties intend to file a supplement to the joint proxy statement/prospectus and mail such supplement to CME and CBOT shareholders as of the record date for the special meetings. This press release is not a substitute for the definitive joint proxy statement/prospectus, as supplemented, or any other documents CME and CBOT have filed or will file with the SEC. Investors and security holders are urged to read the definitive joint proxy statement/prospectus, as supplemented, and any other relevant documents filed or to be filed by CME or CBOT because they contain or will contain important information about the proposed transaction. The definitive joint proxy statement/prospectus is, and the supplement thereto and other documents filed or to be filed by CME and CBOT with the SEC are or will be, available free of charge at the SEC's Web site (www.sec.gov) or from Chicago Mercantile Exchange Holdings Inc., Shareholder Relations and Membership Services, 20 South Wacker Drive, Chicago, Illinois 60606, Attention: Beth Hausoul.

CME and its directors, executive officers and other employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information regarding CME's directors and executive officers is available in CME's proxy statement for its 2007 annual meeting of shareholders, dated March 17, 2007. Additional information regarding the interests of such potential participants is available in the definitive joint proxy statement/prospectus, as supplemented, and the other relevant documents filed with the SEC.

Statements included in this press release relating to the ICE offer reflect the views of CME's management.

This document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S.

Securities Act of 1933, as amended.

CME/CBOT:
A Combination to Compete Successfully
in the Global Marketplace
Presentation to ISS
Craig Donohue, CEO

©
Chicago Mercantile Exchange Inc. All rights reserved.

2

Discussion of Forward-Looking Statements

Forward-Looking Statements

This presentation may contain forward-looking information regarding Chicago Mercantile Exchange Holdings Inc. and CBOT and the combined company after the completion of the merger that

are intended to be covered by the safe harbor for forward-looking statements

provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the benefits of the business combination transaction involving CME and CBOT, including future financial and operating results, the company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based on current beliefs, expectations, forecasts and assumptions of CME and CBOT's

management which are subject to risks and uncertainties

which could cause actual outcomes and result to differ materially from these statements. Other risks and uncertainties relating to the proposed transaction include, but are not limited to the satisfaction of conditions to closing; including receipt of shareholder, merger, antitrust, regulatory and other approvals on the proposed terms;

the proposed transaction may not be consummated on the proposed

terms; uncertainty of the expected financial performance of CME following completion of the proposed transaction; CME may not be able to

achieve the expected cost savings, synergies and other strategic

benefits as a result of the proposed transaction; the integration of CBOT

with CME's

operations may not be successful or may be materially delayed or may be more costly or difficult than expected; general

industry and market conditions; general domestic and international economic conditions; and governmental laws and regulations affecting domestic and foreign operations.

For more information regarding other related risks, see Item 1A of CME's

Annual Report on Form 10-K for the fiscal year ended December

31, 2006. Copies of said 10-K is available online at <http://www.sec.gov>

or on request from the CME. You should not place undue reliance

on forward-looking statements, which speak only as of the date of this presentation. Except for any obligation to disclose material

information under the Federal securities laws, CME undertakes no

obligation to release publicly any revisions to any forward-looking

statements to reflect events or circumstances after the date of this presentation.

Additional Information

CME and CBOT have filed a definitive joint proxy statement/prospectus with the Securities and Exchange Commission (SEC)

with the proposed transaction. The parties intend to file a supplement to the joint proxy statement/prospectus and mail such supplement

to CME and CBOT shareholders as of the record date for the special meetings. This press release is not a substitute for the definitive

proxy statement/prospectus, as supplemented, or any other documents CME and CBOT have filed or will file with the SEC. In addition,

and

security holders are urged to read the definitive joint proxy statement/prospectus, as supplemented, and any other relevant documents

filed or to be filed by CME or CBOT because they contain or will

contain important information about the proposed transaction. The

definitive joint proxy statement/prospectus is, and the supplement thereto and other documents filed or to be filed by CME and CBOT

with the SEC are or will be, available free of charge at the SEC's

Web site (www.sec.gov) or from Chicago Mercantile Exchange Holdings Inc.,

Shareholder Relations and Membership Services, 20 South Wacker

Drive, Chicago, Illinois 60606, Attention: Beth Hausoul.

CME and its directors, executive officers and other employees may be deemed to be participants in the solicitation of proxies in

connection

with the proposed transaction. Information regarding CME's

directors and executive officers is available in CME's

proxy statement for its

2007 annual meeting of shareholders, dated March 17, 2007. Additional information regarding the interests of such potential proxy

holders is available in the definitive joint proxy statement/prospectus,

as supplemented, and the other relevant documents filed with the SEC.

Statements included in this press release relating to the ICE offer reflect the views of CME's

management.

This document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

©
Chicago Mercantile Exchange Inc. All rights reserved.

3
Comparison of Price/Earnings Ratios

17.3

24.0

Nasdaq

19.4
21.9
DBAG
23.0
30.9
NYSE Euronext
36.1
42.5
BOT
37.1
51.2
NMX
27.4
35.3
CME
Price/Earnings Ratio
2008
2007
32.1
46.8
ICE
ICE s

P/E ratios are out of range from their exchange peers

Note: Source CME/CBOT S-4 Filing and Reuters, based on closing prices as of 06/07/21

Take over
speculations drive
price/earnings
ratios
Historically, CME
has had a P/E ratio
higher than ICE

©
Chicago Mercantile Exchange Inc. All rights reserved.
4
ICE
CME
Value Comparison from an Institutional Shareholder
Perspective

CME stock price

(tender offer)

\$560.00

Implied offer price

\$196.00

Plus dividend

\$9.14

Value to institutional

shareholder

\$205.14

On a risk adjusted basis, taking into consideration

long term growth opportunities, integration risks

and currency risks, CME's

offer is superior

* estimated by Mike Vinciguerra, BMO Capital Markets (6/15/07)

Analysts have raised concerns about ICE's

integration capabilities and current valuation ...

ICE stock price

(06/21/07 close)

\$158.55

Implied offer price

\$225.14

Less takeover premium

(15%* to 5% assumed)

\$(34) -

\$(11)

Less breakup fee

(\$294m)

(\$5.54)

Less funding of ERP

solution (16% of \$333m)

(\$3.35)

Value to institutional

shareholder

\$182.48-\$205.00

©
Chicago Mercantile Exchange Inc. All rights reserved.

5

Risks to ICE Value

If it became evident ICE would win [CBOT], ICE stock would fall substantially, perhaps to \$135 or \$140.

~Mike Vinciguerra, BMO Capital Markets (6/15/07)

We continue to highlight ICE's merger proposal for CBOT as the greatest near-term risk to our thesis.

~Credit Suisse (6/13/07)

We believe any alternative transaction [to the CME / CBOT transaction] would take on significantly higher clearing integration risk.

~Credit Suisse (6/13/07)

The most important and contentious points in the ICE offer, namely the integration plans and promises (timing, risk, and synergies), are unchanged.

~Fox-Pitt, Kelton

(6/13/07)

Recent analysts

concerns

... nor does ICE have the scale, scope or reach to mitigate these potential risks

\$140

\$160

\$180

\$200

\$220

ICE Stock Price

No Longer Driven by Fundamentals

G

[A] 5/11: CME increases exchange ratio to 0.3500x

[B] 5/15: ICE announces 6/15 launch of Electronic NYBOT financial products

[C] 5/21: N. Chai, CFO of NYX, states ICE put itself in play

[D] 5/24: ICE announces it will hold CBOT member meeting

[E] 5/30: ICE and CBOE execute agreement regarding ERP

[F] 5/31: ICE holds meeting with CBOT members

[G] 6/4: ICE announces acquisition of ChemConnect; record May volume

[H] 6/11: DOJ approves CME/CBOT merger

[I] 6/12: ICE announces enhanced merger proposal

[J] 6/14: CME/CBOT announce revised merger agreement

[K] 6/18: ICE announces exclusive Russell license

F

ICE Spot

ICE implied

BOT Spot

A

C

Note: CME implied is based on a 0.3500x exchange ratio

B

D

E

H

I

J

K

ICE s

stock has take-over premium built into its price

©
Chicago Mercantile Exchange Inc. All rights reserved.

7

ICE's

Current Stock Price / Takeover Premium

If it became evident ICE would win [CBOT], ICE stock would fall substantially, perhaps to \$135 or \$140.

~Mike Vinciguerra, BMO Capital Markets (6/15/07)

We believe that the current merger filled environment could produce a bidder for ICE as globalization in the sector appears to be just getting started.

~Wachovia (5/3/07)

We believe that ICE's stock has traded higher since the CME revised offer in expectation that ICE would not succeed in its bid attempt and would itself become a takeover target.

~Credit Suisse (6/13/07)

Analysts believe there could be up to a 15% takeover premium in ICE's stock price

Recent analysts

comments on takeover premium

©
Chicago Mercantile Exchange Inc. All rights reserved.

8

Currency Risks in NYSE / Euronext

Transaction

(\$ in millions, except per share amounts)

NYX Annotated Stock Price Chart

ICE Annotated Stock Price Chart

NYX stock has declined by 25% since Euronext
shareholders approved transaction....

12/31/07
Announcement
Date
Shareholder vote
5/22/2006
8/29/2006
12/6/2006
3/15/2007
6/22/2007
\$40
\$50
\$60
\$70
\$80
\$90
\$100
\$110
\$120
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
Price
Volume
Volume Traded
NYSE Euronext
3/15/2007
5/11/2007
7/6/2007
9/3/2007
\$120
\$125
\$130
\$135
\$140
\$145
\$150
\$155
\$160
0
2,000
4,000
6,000
8,000
10,000

12,000

14,000

Price

Volume

Volume Traded

IntercontinentalExchange

Inc.

Shareholder vote

... if the 15% takeover premium comes out of ICE s

stock, CBOT

shareholders would receive \$24 less per share / \$1.7B in aggregate

©
Chicago Mercantile Exchange Inc. All rights reserved.

9
Pro Forma Q107 ADV
6,454
741
3,866

3,866

0

2,000

4,000

6,000

8,000

10,000

12,000

CBOT/CME

Eurex

CBOT/ICE

Euronext.liffe

NYMEX

CME/CBOT Proposed Merger

contracts in 000s

10,320

4,607

Note:

[1] Eurex

and Euronext.liffe

include individual equity and equity index options

[2] NYMEX includes Clearport

[3] Sources are company press releases and analyst presentations

7,295

3,431

1,512

CME and CBOT will create

the largest exchange in the world

©
Chicago Mercantile Exchange Inc. All rights reserved.
10
CME
CBOT
ICE
CBOT

CME/CBOT Proposed Merger

CBOT/CME have much greater presence

across all major asset classes and are well positioned to

leverage significant new growth opportunities

CBOT/ICE

CBOT/CME

Note: CME ADV includes NYMEX products on CME Globex and ICE ADV

includes ICE futures and NYBOT futures and options on futures

Q1 2007 Combined ADV by Product Line (*in 000 s*)

0

2,000

4,000

6,000

8,000

8,000

6,000

4,000

2,000

0

Interest

Rates

Equities

FX

Comm

Energy

Metals

6,671

2,305

555

724

586

154

3,032

142

15

818

531

65

Comm

Energy

Metals

Interest

Rates

Equities

FX

©
Chicago Mercantile Exchange Inc. All rights reserved.
11
May07 ADV 6.1M
3
rd
highest month
Jun07 ADV to date
9.1M
CME Globex

®
(electronic)
CME Average Daily Volume
Open Outcry
Privately Negotiated
(contracts in 000 s)
6,358
03
02
01
00
04
917
05
06
07
(contracts in 000 s)
Annual
Long Term
Monthly
Short Term
CME
ICE Futures
Jan
07
Mar
07
May
07
Jun
07
MTD
Apr
07
Feb
07
52%
0%
0
2,000
4,000
6,000
8,000
74%
0
2,000
4,000
6,000
8,000

©
Chicago Mercantile Exchange Inc. All rights reserved.
12
CME's Growth Strategy

Globalizing our business

Being a leading service provider of
transaction processing services

Expanding into over-the-counter/spot
markets

Leading product and technology innovation
CME will be the leading global derivatives company by:

©
Chicago Mercantile Exchange Inc. All rights reserved.
13
Globalizing Our Business
CME Globex live
access from more
than 80 countries

7 European/
Asian hubs

Regionally focused
sales, education and
marketing to key targets

Broadening relationships
in emerging markets
CME provides access to highly liquid markets across all major
asset classes on an industry leading technology platform

Interest rates

Equities

Foreign exchange

Agricultural commodities

Alternative investments

Energy

Metals

©
Chicago Mercantile Exchange Inc. All rights reserved.
14

Future opportunities in
Asia, South America and
possibly Europe

Leading Service Provider in Transaction Processing

Treasuries

Ags

Equities

Metals

Energy

Metals

Soft Commodities
Transaction Processing
Customer Benefits

Scalable platforms

Advanced functionality

CME customer service
standards

Broad distribution/network
effects

Proven integration/ time-to-
market advantages

Increased profit potential
through CME scale
advantages

©
Chicago Mercantile Exchange Inc. All rights reserved.
15
NYMEX on CME Globex Leads Electronic Energy Trading
601
79
524

334

0

160

320

480

640

Q206

Q306

Q406

Q107

Q207

to date

Total Energy ADV

(contracts in thousands)

NYMEX Energy

on CME Globex

ICE Futures

NYMEX began trading on CME

Globex

on June 12, 2006

©
Chicago Mercantile Exchange Inc. All rights reserved.
16
Significant Opportunities In Larger OTC/Spot Markets

OTC Foreign Exchange

OTC Interest Rate Swaps

\$2

trillion

\$1

trillion

\$0.5

trillion

\$0.1

trillion

\$0.05

trillion

Global

FX

OTC

Interest Rates

US

Treasuries

US

Equities

Europe, Middle East

& Africa

Equities

Average Daily Turnover

Source: BIS 2004 Triennial Survey, SIA, Federal Reserve Bank of New York & World Federation of Exchanges
Celent Report

©
Chicago Mercantile Exchange Inc. All rights reserved.
17
OTC/Spot Market Opportunities

Client acquisition and participation on the platform
is continuing to diversify; pipeline is strong

Liquidity is building; customers expressing satisfaction with bid/ask spreads and depth of book

Broad geographic reach
Favorable Market Trends

Electronic

Centralized clearing

Algorithmic trading

Transparency/anonymity

\$0

\$150

\$300

\$450

\$600

\$750

\$900

\$1,050

\$1,200

\$1,350

Apr-07

May-07

June-07

MTD

\$331

\$509

ADV

(notional value in millions, USD)

\$1,206

©
Chicago Mercantile Exchange Inc. All rights reserved.
18
\$0
\$50
\$100
\$150

\$200

\$250

\$300

Interest Rate

Market

FX Market

Credit Market

Equity Market

Commodity

Market

Larger, More Valuable OTC Growth Opportunities

ICE

Opportunities

Source: June 2006 Notional Value Outstanding per March 2007 BIS

Quarterly Review

CBOT/CME

Opportunities

CBOT/CME is better positioned to immediately pursue the full scope of OTC growth opportunities

\$262

trillion

\$38

trillion

\$20

trillion

\$7

trillion

\$6

trillion

©
Chicago Mercantile Exchange Inc. All rights reserved.

19

Summary Timeline

Original merger agreement -

October 17, 2006

ICE offer rejected by CBOT -

May 11, 2007

Revised merger agreement -

May 11, 2007

DOJ clearance of merger agreement -

June 11, 2007

Revised ICE offer rejected -

June 14, 2007

CME/CBOT cash dividend

and ERP solution adopted -

June 14, 2007

CBOT member and

CME/CBOT shareholder votes -

July 9, 2007

Post-close, CME/CBOT in a position to integrate quickly and smoothly, while maintaining focus on growth initiatives